References
1. Samalin L, Garay R, Ameg A and Llorca PM. Olanzapine pamoate for the
treatment of schizophrenia–a safety evaluation. Expert opinion
on drug safety . 2016;15:403-11.
2. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ
and Corya SA. Post-injection delirium/sedation syndrome in patients with
schizophrenia treated with olanzapine long-acting injection, I: analysis
of cases. BMC Psychiatry . 2010;10:43.
3. McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J,
Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S and Mitchell MI.
Post-injection delirium/sedation syndrome in patients with schizophrenia
treated with olanzapine long-acting injection, II: investigations of
mechanism. BMC Psychiatry . 2010;10:45.
4. Novakovic V, Adel T, Peselow E and Lindenmayer JP. Long-acting
injectable antipsychotics and the development of postinjection
delirium/sedation syndrome (PDSS). Clinical neuropharmacology .
2013;36:59-62.
5. Đorđević S VN, Antunović M, Kilibarda V, Ercegović GV, Stošić JJ,
Vučinić S. Olanzapine poisoning in patients treated at the National
Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief
review of serum concentrations and clinical symptoms. Arh Hig Rada
Toksikol 2022;73:126-130.
6. Palenzona S, Meier PJ, Kupferschmidt H and Rauber-Luethy C. The
clinical picture of olanzapine poisoning with special reference to
fluctuating mental status. Journal of toxicology Clinical
toxicology . 2004;42:27-32.
7. Luedecke D, Schottle D, Karow A, Lambert M and Naber D.
Post-injection delirium/sedation syndrome in patients treated with
olanzapine pamoate: mechanism, incidence, and management. CNS
drugs . 2015;29:41-6.
8. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A,
Frucht S, Gupta S, Levenson JL, Mahmood A, Mann SC, Policastro MA,
Rosebush PI, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB
and Wilkinson JR. An international consensus study of neuroleptic
malignant syndrome diagnostic criteria using the Delphi method. J
Clin Psychiatry . 2011;72:1222-8.
9. Meyers KJ, Upadhyaya HP, Landry JL, Chhabra-Khanna R, Falk DM,
Seetharama Rao B and Jones ME. Postinjection delirium/sedation syndrome
in patients with schizophrenia receiving olanzapine long-acting
injection: results from a large observational study. BJPsych
Open . 2017;3:186-192.
10. Bushe CJ, Falk D, Anand E, Casillas M, Perrin E, Chhabra-Khanna R
and Detke HC. Olanzapine long-acting injection: a review of first
experiences of post-injection delirium/sedation syndrome in routine
clinical practice. BMC Psychiatry . 2015;15:65.
11. Boley SP, Olives TD, Bangh SA, Fahrner S and Cole JB. Physostigmine
is superior to non-antidote therapy in the management of antimuscarinic
delirium: a prospective study from a regional poison center.Clinical toxicology . 2019;57:50-55.
12. Van Kernebeek MW, Ghesquiere M, Vanderbruggen N, Verhoeven E,
Hubloue I and Crunelle CL. Rivastigmine for the treatment of
anticholinergic delirium following severe procyclidine intoxication.Clinical toxicology . 2021;59:447-448.
13. Hughes AR, Moore KK, Mah ND, Birmingham AR, Clark RK, Jr., Thompson
JA and Hendrickson RG. Letter in response to Rivastigmine for the
treatment of anticholinergic delirium following severe procyclidine
intoxication. Clinical toxicology . 2021;59:855-856.
14. Reji KK, Mathew V, Zachariah A, Patil AK, Hansdak SG, Ralph R and
Peter JV. Extrapyramidal effects of acute organophosphate poisoning.Clinical toxicology . 2016;54:259-65.